Dosing Begins in Phase 1 Trial for PTC’s Experimental Parkinson’s Therapy PTC857
The first participant has been dosed in a Phase 1 clinical trial evaluating the safety of PTC857, PTC Therapeutics‘ investigational therapy for Parkinson’s disease. In addition to safety, the trial, which is being conducted in healthy volunteers, will evaluate how the therapy affects and is processed by the…